Gross-to-Net

The discount between a drug’s list price and what the manufacturer actually receives, after rebates to payers and pharmacy benefit managers, discounts, chargebacks and co-pay assistance. Commonly 20% to 50% in the US and growing over a product’s life. A launch curve built on the gross price overstates revenue by exactly this margin.

Where Gross-to-Net comes up

See it built in a working model

Keep reading

Healthcare financial models

Related Healthcare terms

Go further than reading

The written material is free. These are the ways to get it applied to your own work.

Browse the full glossary: 416 finance recruiting and technical terms, in plain English.